AbstractBySubCategory

Translational Research

Cancers of the Esophagus and Stomach

2017 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. Kei Muro

03

Molecular characterization of early vs. late onset gastroesophageal cancers. Sadaf Qureshi

46

Cell free circulating tumor DNA (ctDNA) landscape in patients with advanced gastroesophageal adenocarcinoma (GEC). Daniel V.T. Catenacci

47

Microarray-based tumor molecular profiling to direct choice of cisplatin plus S-1 or oxaliplatin plus S-1 for advanced gastric cancer: A multicentre, prospective, proof-of-concept phase 2 trial. Wei-Peng Yong

48

Combined analysis of three randomized phase III trials comparing S-1 monotherapy and S-1 combination therapy for first-line treatment of advanced gastric cancer. Madoka Takeuchi

49

Analysis of PDL1 expression and T cells infiltration in 1014 gastric cancer patients. Xiaofang Xing

50

Association of specific gene expression profiles with a pathologic complete response to neoadjuvant therapy in esophageal adenocarcinoma. Patrick James McLaren

51

Molecular staging of gastric cancer with a novel panel of prognostic microRNAs. Yanghee Woo

52

Phase II study of conversion therapy using S1/paclitaxel chemotherapy plus apatinib in unresectable gastric cancer (Ahead-G325 trial). Xiangdong Cheng

53

Association of PIK3CA H1047R and STK11 F354L mutations with response to neoadjuvant chemoradiotherapy and survival in esophageal cancer. Po Kuei Hsu

55

A phase II Study of FOLFOX versus POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel) plus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): A feasibility analysis. Rongbo Lin

56

Impact of extra-nodal metastasis on survival in gastric cancer patients with lymph node involvement. Noriyuki Nishiwaki

57

Evaluating collagen neoepitopes as pharmacodynamic biomarkers of GS-5745, an MMP9 inhibitor, in advanced gastric cancer. Carrie Baker Brachmann

58

Quantitative proteomic analysis of TUBB3 to identify gastric cancer patients who may benefit from docetaxel: A reevaluation of the ITACA-S trial. Fabiola Cecchi

59

Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. Steven Brad Maron

60

Association of chromosome 17 copy number instability with favorable prognosis in nonsurgically treated gastroesophageal adenocarinoma and impaired response to trastuzumab. Neal Spada

61

National trends in local excision and esophagectomy for cT1N0 esophageal cancer. Emily C. Sturm

62

Development of a small molecule drug for EBV-associated gastric cancers. Troy E Messick

63

Whole-exome sequencing in radically resected gastric cancer (GC): Analysis of patients (pts) with poor prognostic factors from the Italian Trial of Adjuvant Chemotherapy Adenocarcinoma (ITACA-S) trial. Maria Di Bartolomeo

64

Molecular profiling of adenocarcinoma of esophagogastric junction. Yun-Suhk Suh

65

Metabolomic profling in gastric cancer tissues using time-of-flight mass spectrometry. Sanae Kaji

66

Molecular and clinical characterization of a claudin (CLDN)-low subtype of gastric cancer (GC). Tomohiro F. Nishijima

67

Association of DOCK6 with cancer stem cell development and as an independent prognostic factor of gastric cancer. Chia-Siu Wang

68

Immunoscore based on PD-L1/PD-1 and CD8+ T cells as prognostic marker for stage II/III gastric cancer. Ti Wen

69

Using NSG recipient mice improves engraftment of gastric cancer patient derived xenografts. Sam C. Wang

70

Overexpression of SETDB1 in relation to poor outcome in gastric carcinoma. Wataru Okajima

71

Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer: Preliminary results. Daisuke Takahari

72

Impact of cyclophilin A on survival in gastric cancer patients who received platinum-based chemotherapy. Chi Hoon Maeng

73

Role of systemic immune-inflammatory index, tumor infiltrating neutrophils and PD-1+ T cells to predict the postoperative recurrence after S-1 adjuvant chemotherapy for gastric cancer: A retrospective study. Hiroaki Tanaka

74

Comparison of early tumor shrinkage between oxaliplatin plus S-1 and cisplatin plus S-1 in first-line chemotherapy with advanced gastric cancer. Hiroki Osumi

75

Effect of arsenic trioxide on epithelial-mesenchymal transition via induction of SH2?containing protein tyrosine phosphatase 1. Jong-Jae Park

76

Rapid characterization of candidate loss of function genes in primary organoid culture. Daniel James Hart

77

Methionine gamma-lyase-encapsulated into red blood cells (ERY-MET) antitumor activity in gastric carcinoma. Vanessa Bourgeaux

78

Sex steroids, sex-binding globulin, and prolactin in tissues of adenocarcinoma and esophageal squamous cell carcinoma. Oleg Ivanovich Kit

79

Using adjacent to tumor samples as normal controls in molecular investigations: Are we missing the earliest biomarkers? Williams Fernandes Barra

80

Clinical significance of intratumoral HER2 heterogeneity (IHH) using endoscopic biopsy specimens in patients with HER2-positive gastric cancer (GC) who received T-mab-based chemotherapy. Shusuke Yagi

81

Pathologic validation of ablation therapy for gastric epithelial neoplasia: comparison of argon plasma coagulations vs. coagulation forceps. Byung-Wook Kim

82

Prognostic value of metastatic tumoral caveolin-1 expression in patients with resected gastric cancer. Der Sheng Sun

83

Free and bound plasmin in esophageal tumors and surrounding tissues in men and women. Oleg Ivanovich Kit

84

Gender differences in hormonal statuses of patients with esophageal squamous cell carcinoma. Evgeniy N. Kolesnikov

85

Angiogenesis factors in esophageal tumors of various histogenesis. Elena Mikhaylovna Frantsiyants

87

Thrombospondin-1 expressions in non-cancer tissue correlated with gastric carcinogenesis. Hideya Kashihara

88

A pilot study of apatinib reversing paclitaxel resistance in heavily pretreated advanced gastric cancer (AGC). Rongbo Lin

89

CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer. Ronan Joseph Kelly

TPS212

Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer. Yelena Yuriy Janjigian

TPS213

Use of circulating tumor DNA levels to gauge necessity of surgery for patients undergoing trimodality therapy for esophageal cancer. Nima Nabavizadeh

TPS214

Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers. Diana Felice Hausman

TPS215